닫기
검색

Antibody

What is a good antibody?

antibody_1.png

Is an antibody with a picomolar target binding affinity better than one with a nanomolar range?
Is an antibody with 15-day in vivo half-life better than one with two days?
What about an antibody with enhanced antibody-dependent cellular cytotoxicity(ADCC)?

The right answers for the above questions are “yes or no”, or “it depends”.
Picomolar affinity is good for an antibody therapy or an antibody-drug conjugate but not for CAR-T.
The longer half-life, usually the better, but you need to shorten the half-life when utilizing the therapeutic antibody for preconditioning purpose. Enhanced ADCC helps to improve anti-cancer effect but could cause inflammation-induced adverse events in a particular condition, i.e. eyes.

A good antibody is defined as its fit for purpose. An expert in antibody discovery and research, we start from designing the “purpose” of an antibody, which requires deep understandings on the mechanism of action, the target’s molecular structure and functionality, potential therapeutic strategies, and applicable modalities.

We are competent in and have procured technical accessibility to wide range of antibody discovery approaches, from phage display library and humanization of non-human antibody to human gene encoded transgenic mouse. Upon discovery, we have proprietary skills and knowhow in immunization and binding affinity maturation.

We think the purpose first, and are good at making good antibodies.